Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 18/20 | 0.57 |
| ▸ | UGCG | Q16739 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19837255 | 0.92 | NTMT1 (0.58) | NTMT1UGCG | |
| SCHEMBL16006997 | 0.86 | NTMT1 (0.66) | NTMT1UGCG | |
| SCHEMBL16006996 | 0.86 | NTMT1 (0.66) | NTMT1UGCG | |
| SCHEMBL12615276 | 0.86 | NTMT1 (0.56) | NTMT1UGCG | |
| SCHEMBL29359523 | 0.85 | NTMT1 (0.54) | NTMT1UGCG | |
| SCHEMBL29400186 | 0.84 | NTMT1 (0.54) | NTMT1UGCG | |
| SCHEMBL15578038 | 0.84 | NTMT1 (0.53) | NTMT1UGCG | |
| SCHEMBL29399635 | 0.84 | NTMT1 (0.53) | NTMT1UGCG | |
| SCHEMBL12614555 | 0.84 | NTMT1 (0.58) | NTMT1UGCG | |
| SCHEMBL29399491 | 0.83 | NTMT1 (0.56) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3920912-B1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GENZYME CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3267983-B1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORP (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GENZYME CORPORATION | 2023-11-23 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220110922-A1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORPORATION (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210251982-A1 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20200197374-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20200124624-A1 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | GENZYME CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GBA1, GBA2, GALC | NTMT1 1645/4885UGCG 20/4885 |
| US-20200124624-A1 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | PSMG3, PMP22, PLP2 | NTMT1 2661/4885UGCG 101/4885 |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GBA1, GBA2, CLN6 | NTMT1 1309/4885UGCG 147/4885 |
| US-20200197374-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | NTMT1 1778/4885UGCG 2762/4885 |
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GBA1, GBA2, GALC | NTMT1 684/4885UGCG 13/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | NTMT1 754/4885UGCG 8/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 795/4885UGCG 4/4885 |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, GALC | NTMT1 2471/4885UGCG 84/4885 |
| US-20210251982-A1 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GBA1, GBA2, CLN6 | NTMT1 1309/4885UGCG 147/4885 |
| US-20220110922-A1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GBA1, GBA2, GALC | NTMT1 1692/4885UGCG 4/4885 |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, CMA1 | NTMT1 1379/4885UGCG 160/4885 |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | NTMT1 1778/4885UGCG 2762/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 795/4885UGCG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.